MNPR
Monopar Therapeutics (MNPR)
$
82About Monopar Therapeutics (MNPR)
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
Details
Daily high
$30.40
Daily low
$23.66
Price at open
$30.40
52 Week High
$38.50
52 Week Low
$1.54
Market cap
136.3M
Dividend yield
0.00%
Volume
139,076
Avg. volume
104,836
P/E ratio
-13.03
Monopar Therapeutics News
Details
Daily high
$30.40
Daily low
$23.66
Price at open
$30.40
52 Week High
$38.50
52 Week Low
$1.54
Market cap
136.3M
Dividend yield
0.00%
Volume
139,076
Avg. volume
104,836
P/E ratio
-13.03